TLR2 and neoplasm: A vaccine comprising bacteria-mimicking tumor cells (BMTC) and P2CSR11/P2CSK11 (TLR2 ligand) promoted anti-tumor immunity by stimulating DCs and enhancing antigen presentation (Akazawa et al., 2018).